These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 24464360

  • 1. Novel drugs targeting transthyretin amyloidosis.
    Hanna M.
    Curr Heart Fail Rep; 2014 Mar; 11(1):50-7. PubMed ID: 24464360
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y.
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H, Hashimoto T, Kawamura S, Hiroe M, Yamashita T, Ando Y, Yokochi T.
    J Med Case Rep; 2018 Dec 16; 12(1):370. PubMed ID: 30553273
    [Abstract] [Full Text] [Related]

  • 7. Sporadic transthyretin amyloidosis with a novel TTR gene mutation misdiagnosed as primary amyloidosis.
    Briani C, Cavallaro T, Ferrari S, Taioli F, Calamelli S, Verga L, Adami F, Fabrizi GM.
    J Neurol; 2012 Oct 16; 259(10):2226-8. PubMed ID: 22580845
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant.
    Yagi S, Yamazaki H, Kusunose K, Osaki Y, Ise T, Kadota M, Tserensonom M, Kawabata Y, Hara T, Ueno R, Saijo Y, Matsuura T, Yamaguchi K, Yamada H, Fukuda D, Soeki T, Wakatsuki T, Sata M.
    J Med Invest; 2022 Oct 16; 69(3.4):320-322. PubMed ID: 36244789
    [Abstract] [Full Text] [Related]

  • 11. Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis.
    Zanazzi G, Arshad M, Maurer MS, Brannagan TH, Tanji K.
    J Clin Neuromuscul Dis; 2019 Mar 16; 20(3):120-128. PubMed ID: 30801482
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD, Dasgupta NR, Rissing SM, Smith J, Feigenbaum H.
    Amyloid; 2017 Dec 16; 24(4):219-225. PubMed ID: 28906150
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J.
    Am J Cardiol; 2021 Jun 01; 148():146-150. PubMed ID: 33667442
    [Abstract] [Full Text] [Related]

  • 16. Exploring Transthyretin Amyloid Cardiomyopathy: A Comprehensive Review of the Disease and Upcoming Treatments.
    Jain H, Reddy MMRK, Dey RC, Jain J, Shakhatreh Z, Manandhar S, Neupane P, Waleed MS, Yadav R, Sah BK, Mahawa R.
    Curr Probl Cardiol; 2024 Jan 01; 49(1 Pt B):102057. PubMed ID: 37640179
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Transthyretin Amyloidosis with Gastrointestinal Manifestation: a Case Report.
    Nakov R, Sarafov S, Nakov V, Gospodinova M, Todorov T, Kirov A, Todorova A, Tournev I.
    J Gastrointestin Liver Dis; 2019 Sep 01; 28(3):359-361. PubMed ID: 31517333
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.